Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT06931080
PHASE2/PHASE3

Evaluation of the Efficacy and Safety of EB-1020 in Adult ADHD Patients

Sponsor: Otsuka Pharmaceutical Co., Ltd.

View on ClinicalTrials.gov

Summary

The purpose of this study is to evaluate the efficacy and examine the safety of two doses of EB-1020 QD XR capsule administered once daily orally in adult ADHD patients.

Official title: A Phase 2/3, Multicenter, Randomized, Double-blind, Placebo-controlled, Trial to Evaluate the Efficacy and Safety of EB-1020 Once Daily QD XR Capsules Administered Orally at Low or High Dose in Adults With Attention-deficit/Hyperactivity Disorder

Key Details

Gender

All

Age Range

18 Years - 55 Years

Study Type

INTERVENTIONAL

Enrollment

630

Start Date

2025-04-30

Completion Date

2027-12

Last Updated

2025-08-03

Healthy Volunteers

No

Interventions

DRUG

EB-1020 (Centanafadine) 164.4 mg

164.4 mg, capsule, oral, once daily, for 6 weeks

DRUG

EB-1020 (Centanafadine) 328.8 mg

328.8 mg, capsule, oral, once daily, for 6 weeks

DRUG

Placebo

Placebo, capsule, oral, once daily, for 6 weeks

Locations (1)

Maynds Tower Mental Clinic

Tokyo, Japan